|
Name |
18-Deoxycytochalasin Q
|
Molecular Formula | C30H37NO5 | |
IUPAC Name* |
[(1R,2R,3E,5S,7S,9E,11R,12S,14R,15S,16R,17S)-17-benzyl-5,7,14,15-tetramethyl-6,19-dioxo-13-oxa-18-azatetracyclo[9.8.0.01,16.012,14]nonadeca-3,9-dien-2-yl] acetate
|
|
SMILES |
C[C@H]1C/C=C/[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2([C@@H](/C=C/[C@@H](C1=O)C)OC(=O)C)C(=O)N[C@H]4CC5=CC=CC=C5)C)C
|
|
InChI |
InChI=1S/C30H37NO5/c1-17-10-9-13-22-27-29(5,36-27)19(3)25-23(16-21-11-7-6-8-12-21)31-28(34)30(22,25)24(35-20(4)32)15-14-18(2)26(17)33/h6-9,11-15,17-19,22-25,27H,10,16H2,1-5H3,(H,31,34)/b13-9+,15-14+/t17-,18-,19-,22-,23-,24+,25-,27-,29+,30+/m0/s1
|
|
InChIKey |
BKYYCQITLVBDMY-YUDFGMRISA-N
|
|
Synonyms |
18-Deoxycytochalasin Q; CHEBI:188769; [(1R,2R,3E,5S,7S,9E,11R,12S,14R,15S,16R,17S)-17-benzyl-5,7,14,15-tetramethyl-6,19-dioxo-13-oxa-18-azatetracyclo[9.8.0.01,16.012,14]nonadeca-3,9-dien-2-yl] acetate
|
|
CAS | NA | |
PubChem CID | 56590339 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 491.6 | ALogp: | 4.2 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 85.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 36 | QED Weighted: | 0.378 |
Caco-2 Permeability: | -4.827 | MDCK Permeability: | 0.00002090 |
Pgp-inhibitor: | 0.992 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.043 | 20% Bioavailability (F20%): | 0.033 |
30% Bioavailability (F30%): | 0.013 |
Blood-Brain-Barrier Penetration (BBB): | 0.533 | Plasma Protein Binding (PPB): | 97.35% |
Volume Distribution (VD): | 1.573 | Fu: | 3.52% |
CYP1A2-inhibitor: | 0.045 | CYP1A2-substrate: | 0.109 |
CYP2C19-inhibitor: | 0.267 | CYP2C19-substrate: | 0.421 |
CYP2C9-inhibitor: | 0.497 | CYP2C9-substrate: | 0.04 |
CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.227 |
CYP3A4-inhibitor: | 0.916 | CYP3A4-substrate: | 0.494 |
Clearance (CL): | 5.288 | Half-life (T1/2): | 0.708 |
hERG Blockers: | 0.082 | Human Hepatotoxicity (H-HT): | 0.962 |
Drug-inuced Liver Injury (DILI): | 0.969 | AMES Toxicity: | 0.016 |
Rat Oral Acute Toxicity: | 0.291 | Maximum Recommended Daily Dose: | 0.862 |
Skin Sensitization: | 0.085 | Carcinogencity: | 0.022 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.906 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002202 | 0.804 | D0V3ZA | 0.260 | ||||
ENC003300 | 0.761 | D0W7RJ | 0.254 | ||||
ENC003712 | 0.750 | D01TSI | 0.253 | ||||
ENC002762 | 0.739 | D09NNH | 0.253 | ||||
ENC005439 | 0.728 | D0SP3D | 0.253 | ||||
ENC001886 | 0.694 | D0TB8C | 0.247 | ||||
ENC004026 | 0.634 | D0R1BD | 0.244 | ||||
ENC005546 | 0.615 | D07HOF | 0.244 | ||||
ENC003229 | 0.612 | D06CWH | 0.244 | ||||
ENC003653 | 0.608 | D00OAY | 0.243 |